SAN JOSE, Calif., March 12, 2018 /PRNewswire/ -- ITUS
Corporation (NASDAQ: ITUS), today announced that it will present
data from its ongoing study utilizing Cchek™, ITUS's artificial
intelligence (AI) driven early cancer detection technology.
The presentation will be made at the annual meeting of the
American Association of Cancer Research (AACR) in Chicago, Illinois. The meeting will be
held April 14-18, 2018 and will be
attended by world leading experts across the field of cancer
research. All abstracts will be viewable by registered
attendees beginning March 14,
2018. To receive a copy of the presentation, please email
your request to AACR-2018@ITUScorp.com starting April 19, 2018 and include your name, title, and
contact information.
The presentation will focus on ITUS' proprietary Cchek™ platform
featuring new data and insights into this early cancer detection
technology. Cchek™ combines the immunophenotyping of white
blood cells using flow cytometry with a proprietary neural network,
a type of artificial intelligence (AI), to detect the presence of
solid tumors from a blood sample. Identifying and measuring
circulating myeloid-derived suppressor cells (MDSCs), a group of
immunosuppressive white blood cells, is the foundation of this
technology.
"We are pleased to be presenting our data at the annual AACR
meeting, the largest yearly scientific meeting for cancer
researchers," stated Dr. Amit Kumar,
President and CEO of ITUS Corporation. "As we continue to
advance our technology, we expect that premier scientific
conferences will enable us to educate the scientific community and
the broader cancer community about our findings."
American Association of Cancer Research (AACR)
The
American Association of Cancer Research (AACR) (www.aacr.org) is a
501(c)(3) public charity headquartered in Philadelphia, PA.
The mission of the AACR is to prevent and cure cancer through
research, education, communication and collaboration. Through
its programs and services, the AACR fosters cancer research and
related biomedical science; accelerates the dissemination of new
research findings among scientists and others dedicated to the
conquest of cancer; promotes science education and training; and
advances the understanding of cancer causes, prevention, diagnosis
and treatment throughout the world. The theme for the 2018
AACR Annual Meeting is "Driving Innovative Cancer Science to
Patient Care."
ITUS Corporation
ITUS, a cancer-focused biotechnology
company, is harnessing the body's immune system in the fight
against cancer. Its wholly owned subsidiary, Anixa
Diagnostics Corporation, is developing the CchekTM
platform, a series of non-invasive blood tests for the early
detection of solid tumor based cancers, which is based on the
body's immunological response to the presence of a
malignancy. Its majority owned subsidiary, Certainty
Therapeutics, Inc., is developing CAR-T based immuno-therapy drugs
which genetically engineer a patient's own immune cells to fight
cancer. ITUS also continually examines emerging technologies
in complementary or related fields for further development and
commercialization. Additional information is available at
www.ITUScorp.com.
Forward-Looking Statements: Statements that are
not historical fact may be considered forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements are not statements of
historical facts, but rather reflect ITUS Corporation's current
expectations concerning future events and results. We generally use
the words "believes," "expects," "intends," "plans," "anticipates,"
"likely," "will" and similar expressions to identify
forward-looking statements. Such forward-looking statements,
including those concerning our expectations, involve risks,
uncertainties and other factors, some of which are beyond our
control, which may cause our actual results, performance or
achievements, or industry results, to be materially different from
any future results, performance, or achievements expressed or
implied by such forward-looking statements. These risks,
uncertainties and factors include, but are not limited to, those
factors set forth in "Item 1A - Risk Factors" and other sections of
our most recent Annual Report on Form 10-K as well as in our
Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We
undertake no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law. You are
cautioned not to unduly rely on such forward-looking statements
when evaluating the information presented in this press
release.
ITUS Corporation: FOCUSED ON INNOVATION™
View original content with
multimedia:http://www.prnewswire.com/news-releases/itus-will-present-data-at-the-american-association-of-cancer-research-aacr-annual-meeting-300611802.html
SOURCE ITUS Corporation